MedTrace Logo

A Study of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise Healthy

NCT07654972 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 108

Last updated 2026-07-16

No results posted yet for this study

Summary

The main purpose of this study is to understand how safe and well-tolerated LY4174794 is in participants with obesity or overweight who are otherwise healthy. Blood tests will be performed to check how much LY4174794 gets into the bloodstream and how long it takes the body to eliminate it.

Participation in this study will last about 35 to 45 weeks (7 to 11 months).

Conditions

Interventions

DRUG

LY4174794

Administered SC.

DRUG

LY4174794

Administered IV.

DRUG

Placebo

Administered SC.

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-06-24
Primary Completion
2029-04-30
Completion
2029-04-30
FDA Drug
Yes

Countries

  • United States
  • Singapore

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07654972 on ClinicalTrials.gov